• Type: Third generation cephalosporin
  • Dosage Forms: tablet, chewable tablet, oral suspension
  • Dosage Strengths: tablet: 400mg; chewable tablet: 100, 200mg; oral suspension: 100mg/5mL, 200mg/5mL, 500mg/mL
  • Routes of Administration: PO
  • Common Trade Names: Suprax

Adult Dosing

Pediatric Dosing

Special Populations

  • Pregnancy:
  • Lactation:
  • Renal Dosing
    • Adult
      • CrCl ≥ 60 mL/min: No adjustment
      • CrCl 21 to 59 mL/min:
        • Chewable tablet: not recommended
        • Suspension: 260 mg once daily
      • CrCl ≤ 20
        • Chewable tablet: 200 mg once daily
        • 100 mg/5 mL suspension: 172 mg once daily
        • 200 mg/5 mL suspension: 176 mg once daily
        • 500 mg/5 mL suspension: 180 mg once daily
      • Hemodialysis
        • Chewable tablet: not recommended
        • Suspension: 260 mg once daily
    • Pediatric
      • limited data
      • Mild to moderate impairment - no adjustment
      • Severe impairment and anuric - reduce dose 50%
  • Hepatic Dosing
    • Adult
      • Not defined
    • Pediatric
      • Not defined


  • Allergy to class/drug

Adverse Reactions




  • Half-life: 3-4 hr
  • Metabolism:
  • Excretion: Urine (50% as unchanged drug), feces (10%)
  • Mechanism of Action: arrests bacterial cell wall synthesis

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae S
Viridans strep S
Strep. anginosus gp X1
Enterococcus faecalis R
Enterococcus faecium X1
Staph. Epidermidis R
C. jeikeium R
L. monocytogenes R
Gram Negatives N. gonorrhoeae S
N. meningitidis I
Moraxella catarrhalis S
H. influenzae S
E. coli S
Klebsiella sp S
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg R
Enterobacter sp, AmpC pos R
Serratia sp I
Serratia marcescens X1
Salmonella sp S
Shigella sp S
Proteus mirabilis S
Proteus vulgaris S
Providencia sp. S
Morganella sp. R
Citrobacter freundii R
Citrobacter diversus X1
Citrobacter sp. S
Aeromonas sp S
Acinetobacter sp. R
Pseudomonas aeruginosa R
Burkholderia cepacia R
Stenotrophomonas maltophilia R
Yersinia enterocolitica S
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida S
Haemophilus ducreyi S
Vibrio vulnificus X1
Misc Chlamydophila sp X1
Mycoplasm pneumoniae X1
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces X1
Bacteroides fragilis R
Prevotella melaninogenica S
Clostridium difficile X1
Clostridium (not difficile) R
Fusobacterium necrophorum X1
Peptostreptococcus sp. S


  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also


  1. Sanford Guide to Antimicrobial Therapy 2014

Cefixime: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019.